Aligos Therapeutics (ALGS) Price to Sales (2021 - 2026)

Aligos Therapeutics (ALGS) has reported Price to Sales for 6 consecutive years, with 27.31 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Price to Sales fell 87.76% year-over-year to 27.31; the trailing twelve-month figure through Jun 2026 stood at 16.09 (down 32.47% YoY), and the FY2025 full-year result was 42.14, down 39.02% from the prior year.
• Price to Sales slipped to 27.31 in Q1 2026 per ALGS's latest filing, from 545.13 in the prior quarter.
• Across five years, Price to Sales topped out at 5512.65 in Q1 2024 and bottomed at 27.31 in Q1 2026.
• Historically, Price to Sales has averaged 682.62 across 5 years, with a median of 350.65 in 2022.
• The sharpest annual moves came in 2022 and 2024: Price to Sales tumbled 99.16% in 2022, then surged 1417.64% in 2024.
• Over 5 years, Price to Sales stood at 289.19 in 2022, then soared by 83.61% to 530.97 in 2023, then retreated by 22.43% to 411.85 in 2024, then surged by 32.36% to 545.13 in 2025, then sank by 94.99% to 27.31 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 27.31, 545.13, and 137.14 for Q1 2026, Q4 2025, and Q3 2025 respectively.